Following is an overview of the clinical quality measures in GIQuIC that can be reported to CMS for the Quality performance category of the Merit-Based Incentive Payment System (MIPS) via the GIQuIC Qualified Clinical Data Registry (QCDR) for the 2019 program year. Additional detail on GIQuIC’s QCDR measures available for public reporting follows on the subsequent pages.

The GIQuIC 2019 QCDR has been approved to support individual eligible clinician, group, and virtual group reporting to the Quality, Improvement Activities, and Promoting Interoperability performance categories.

<table>
<thead>
<tr>
<th>Measure #</th>
<th>Title</th>
<th>Outcome/High-Priority</th>
</tr>
</thead>
<tbody>
<tr>
<td>QPP343</td>
<td>Screening Colonoscopy Adenoma Detection Rate</td>
<td>Outcome</td>
</tr>
<tr>
<td>QPP425</td>
<td>Photodocumentation of Cecal Intubation</td>
<td>N/A</td>
</tr>
<tr>
<td>QPP320</td>
<td>Appropriate follow-up interval for normal colonoscopy in average risk patients</td>
<td>High-Priority</td>
</tr>
<tr>
<td>GIQIC15</td>
<td>Appropriate follow-up interval of 3 years recommended based on pathology findings from screening colonoscopy in average-risk patients</td>
<td>High-Priority</td>
</tr>
<tr>
<td>GIQIC17</td>
<td>Appropriate follow-up interval of 5 years for colonoscopies with findings of sessile serrated polyps &lt; 10 mm without dysplasia</td>
<td>High-Priority</td>
</tr>
<tr>
<td>GIQIC21</td>
<td>Appropriate follow-up interval of not less than 5 years for colonoscopies with findings of 1-2 tubular adenomas &lt; 10 mm OR of 10 years for colonoscopies with only hyperplastic polyp findings in rectum or sigmoid</td>
<td>High-Priority</td>
</tr>
<tr>
<td>NHCR4</td>
<td>Repeat screening or surveillance colonoscopy recommended within one year due to inadequate/poor bowel preparation</td>
<td>High-Priority</td>
</tr>
<tr>
<td>GIQIC12</td>
<td>Appropriate indication for colonoscopy</td>
<td>N/A</td>
</tr>
<tr>
<td>GIQIC19</td>
<td>Appropriate indication for esophagogastroduodenoscopy (EGD)</td>
<td>N/A</td>
</tr>
<tr>
<td>GIQIC10</td>
<td>Appropriate management of anticoagulation in the peri-procedural period rate – EGD</td>
<td>High-Priority</td>
</tr>
</tbody>
</table>
GIQIC15: Appropriate follow-up interval of 3 years recommended based on pathology findings from screening colonoscopy in average-risk patients

**Description:** Percentage of average-risk patients aged 50 years and older receiving a screening colonoscopy with biopsy or polypectomy and pathology findings of 3-10 adenomas, Advanced Neoplasm (≥ 10 mm, high grade dysplasia, villous component), Sessile serrated polyp ≥ 10 mm OR sessile serrate polyp with dysplasia OR traditional serrated adenoma who had a recommended follow-up interval of 3 years for repeat colonoscopy

**Denominator:** All complete and adequately prepped screening colonoscopies of average-risk patients aged 50 years and older with biopsy or polypectomy and pathology findings of 3-10 adenomas, OR Advanced Neoplasm (≥ 10 mm, high grade dysplasia, villous component) OR Sessile serrated polyp ≥ 10 mm OR sessile serrated polyp with dysplasia OR traditional serrated adenoma

**Denominator Exceptions:** None

**Denominator Exclusions:** None

**Numerator:** Number of average-risk patients aged 50 years and older receiving a complete and adequately prepped screening colonoscopy with biopsy or polypectomy and pathology findings of 3-10 adenomas OR Advanced Neoplasm (≥ 10 mm, high grade dysplasia, villous component) OR Sessile serrated polyp ≥ 10 mm OR sessile serrated polyp with dysplasia OR traditional serrated adenoma who had a recommended follow-up interval of 3 years for repeat colonoscopy

**Rationale and Supported Evidence:**

The Guidelines for Colonoscopy Surveillance After Screening and Polypectomy: Consensus Update by the US Multi-society Task Force on Colorectal Cancer\(^1\) presents recommendations for surveillance intervals in individuals with baseline average risk. Colonoscopies should follow recommended post-polypectomy surveillance intervals to be clinically effective and to minimize risk and further to be cost-effective. Average-risk patients aged 50 years and older receiving a screening colonoscopy with biopsy or polypectomy and pathology findings of 3-10 adenomas, advanced neoplasm (≥ 10 mm, high grade dysplasia, villous component), sessile serrated polyp ≥ 10 mm OR sessile serrate polyp with dysplasia or traditional serrated adenoma should receive a recommended follow-up interval of 3 years for repeat colonoscopy.

---

**GIQIC17**: Appropriate Follow-Up Interval of 5 Years for Colonoscopies with findings of Sessile Serrated Polyps < 10 mm without dysplasia

**Description**: Percentage of average-risk patients aged 50 years and older receiving a screening colonoscopy with biopsy or polypectomy and pathology findings of sessile serrated polyp(s) < 10 mm without dysplasia with a recommended follow-up interval of 5 years for repeat colonoscopy documented in their colonoscopy report.

**Denominator**: All complete and adequately prepped screening colonoscopies of average-risk patients aged 50 years and older with biopsy or polypectomy and pathology findings of sessile serrated polyp < 10 mm without dysplasia

**Denominator Exceptions**: None

**Denominator Exclusions**: None

**Numerator**: Number of average-risk patients aged 50 years and older receiving a complete and adequately prepped screening colonoscopy with biopsy or polypectomy and pathology findings of sessile serrated polyp < 10 mm without dysplasia who had a recommended follow-up interval of 5 years for repeat colonoscopy

**Rationale and Supported Evidence**:

The *Guidelines for Colonoscopy Surveillance After Screening and Polypectomy: Consensus Update by the US Multi-society Task Force on Colorectal Cancer*¹ presents recommendations for surveillance intervals in individuals with baseline average risk. Colonoscopies should follow recommended post-polypectomy surveillance intervals to be clinically effective and to minimize risk and further to be cost-effective. Average-risk patients aged 50 years and older receiving a screening colonoscopy with biopsy or polypectomy and pathology findings of sessile serrated polyp(s) < 10 mm with no dysplasia should receive a recommended follow-up interval of 5 years for repeat colonoscopy.
GIQIC21: Appropriate follow-up interval of not less than 5 years for colonoscopies with findings of 1-2 tubular adenomas < 10 mm OR of 10 years for colonoscopies with only hyperplastic polyp findings in rectum or sigmoid

**Description:** Percentage of average-risk patients aged 50 years to 75 years receiving a screening colonoscopy with biopsy or polypectomy and pathology findings of 1 of 2 tubular adenomas < 10 mm with a recommended follow-up interval of not less than 5 years OR pathology findings of only hyperplastic polyp findings in rectum or sigmoid with a recommended follow-up interval of 10 years for repeat colonoscopy documented in their colonoscopy report.

**Denominator:** All complete and adequately prepped screening colonoscopies of average risk patients aged 50 years to 75 years with biopsy or polypectomy and pathology findings of: (Strata 1) 1 to 2 tubular adenomas < 10 mm OR (Strata 2) only hyperplastic polyp(s) in rectum or sigmoid

**Denominator Exceptions:** Patients aged 66 to 75

**Denominator Exclusions:** None

**Numerator:** Number of average-risk patients aged 50 years to 75 years receiving a complete and adequately prepped screening colonoscopy with biopsy or polypectomy and: (Strata 1) pathology findings of 1 to 2 tubular adenomas < 10 mm who had a recommended follow-up interval of ≥ 5 years for repeat colonoscopy OR (Strata 2) pathology findings of only hyperplastic polyp(s) in rectum or sigmoid who had a recommended follow-up interval of 10 years for repeat colonoscopy documented in their colonoscopy report

**Rationale and Supported Evidence:**

The *Guidelines for Colonoscopy Surveillance After Screening and Polypectomy: Consensus Update by the US Multi-society Task Force on Colorectal Cancer* presents recommendations for surveillance intervals in individuals with baseline average risk. Colonoscopies should follow recommended post-polypectomy surveillance intervals to be clinically effective and to minimize risk and further to be cost-effective. Average-risk patients aged 50 years and older receiving a screening colonoscopy with biopsy or polypectomy and pathology findings of 1-2 small (< 10 mm) tubular adenomas should receive a recommended follow-up interval of 5 to 10 years for repeat colonoscopy. Average-risk patients aged 50 years and older receiving a screening colonoscopy with biopsy or polypectomy and pathology findings of distal small lesions (<10 mm) hyperplastic polyps should receive a recommended follow-up interval of 10 years for repeat colonoscopy.
**NHCR4:** Repeat screening or surveillance colonoscopy recommended within one year due to inadequate/poor bowel preparation

**Description:** Percentage of patients recommended for repeat screening or surveillance colonoscopy within one year or less due to inadequate/poor bowel preparation quality

**Denominator:** # of screening and surveillance colonoscopies with bowel preparation documented as inadequate/poor

**Denominator Exceptions:** None

**Denominator Exclusions:** None

**Numerator:** # of screening and surveillance colonoscopies with bowel preparation documented as inadequate/poor and whose recommended follow-up was ≤ 1 year

**Rationale and Supported Evidence:**
Colonoscopies with poor bowel preparation are considered incomplete due to inadequate mucosal visualization, and shorter follow-up intervals are recommended to ensure effective care.
GIQIC12: Appropriate indication for colonoscopy

**Description:** Percentage of colonoscopy procedures performed for an indication that is included in a published standard list of appropriate indications and the indication is documented

**Denominator:** All colonoscopies

**Denominator Exceptions:** None

**Denominator Exclusions:** None

**Numerator:** Number of colonoscopies performed for an indication that is included in a published standard list of appropriate indications

**Rationale and Supporting Evidence:**

In 2012, ASGE updated its indications for endoscopic procedures, Appropriate Use of Gastrointestinal Endoscopy.\(^2\) This list was determined by a review of published literature and expert consensus. Studies have shown that when colonoscopy is done for appropriate reasons, significantly more clinically relevant diagnoses are made.\(^3,4,5\)

Based on the evidence GIQuIC’s supporting societies agree the performance target for an appropriate indication measure should be > 80%.

---


GIQIC19: Appropriate Indication for Esophagogastroduodenoscopy (EGD)

Description: Percentage of esophagogastroduodenoscopy (EGD) procedures performed for an indication that is included in a published standard list of appropriate indications and the indication is documented.

Denominator: All EGDs

Denominator Exceptions: None

Denominator Exclusions: None

Numerator: Number of EGDs performed for an indication that is included in a published standard list of appropriate indications.

Rationale and Supporting Evidence:

In 2012, ASGE updated its indications for endoscopic procedures, Appropriate Use of Gastrointestinal Endoscopy.\textsuperscript{3} This list was determined by a review of published literature and expert consensus. Studies have shown that when colonoscopy is done for appropriate reasons, significantly more clinically relevant diagnoses are made.\textsuperscript{4,5,6}

Based on the evidence GIQuIC’s supporting societies agree the performance target for an appropriate indication measure should be > 80%.
GI Quality Improvement Consortium, Ltd. (GIQuIC)  
2019 QCDR Measures

**GIQIC10**: Appropriate management of anticoagulation in the peri-procedural period rate – EGD

**Description**: Percentage of patients undergoing an EGD on an anti-platelet agent or an anticoagulant who leave the endoscopy unit with instructions for management of this medication

**Denominator**: All patients undergoing an EGD on an anti-platelet agent or an anticoagulant

**Denominator Exceptions**: None

**Denominator Exclusions**: None

**Numerator**: Number of patients on an anti-platelet agent or an anticoagulant who leave the endoscopy unit with instructions for management of this medication

**Rationale and Supported Evidence**:

Given bleeding is an adverse event associated with EGD,\(^6,7,8\), adherence to this quality measure is supported by GIQuIC for this population of patients.

---

